Announced Securities Purchase Agreement For Up To $20 Million with Aspire Capital Fund, LLC NEW YORK and LONDON , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to
NEW YORK and LONDON , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics , Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement
NEW YORK and LONDON , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement
Combined inhibition of LTB4 and C5 by Coversin showed reversal of disease symptoms in preclinical rheumatoid arthritis (RA) model Ex vivo data from bullous pemphigoid (BP) patients showed presence of both LTB4 and C5 at similar elevated concentrations These new data support the potential advantage
Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial for PNH patients resistant to treatment with
NEW YORK and LONDON , June 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announces it will be presenting an
NEW YORK and LONDON , May 21, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that as a result of its
Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naïve Trial CAPSTONE, the Phase III Naïve PNH Trial Expected to Open in Q1 2018 Phase II PNH Trial Completed With Primary Endpoint Met Phase II aHUS Trial Initiated End of 2017 U.S.
NEW YORK and LONDON , March 16, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that the Company will report
NEW YORK and LONDON , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced
